These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 25311381)

  • 1. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.
    Siddiqui MS; Fuchs M; Idowu MO; Luketic VA; Boyett S; Sargeant C; Stravitz RT; Puri P; Matherly S; Sterling RK; Contos M; Sanyal AJ
    Clin Gastroenterol Hepatol; 2015 May; 13(5):1000-8.e3. PubMed ID: 25311381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
    Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
    J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis.
    Siddiqui MS; Sterling RK; Luketic VA; Puri P; Stravitz RT; Bouneva I; Boyett S; Fuchs M; Sargeant C; Warnick GR; Grami S; Sanyal AJ
    Gastroenterology; 2013 Dec; 145(6):1271-9.e1-3. PubMed ID: 23973920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein Profiles in Class III Obese Caucasian and African American Women with Nonalcoholic Fatty Liver Disease.
    Garcia AE; Kasim N; Tamboli RA; Gonzalez RS; Antoun J; Eckert EA; Marks-Shulman PA; Dunn J; Wattacheril J; Wallen T; Abumrad NN; Flynn CR
    PLoS One; 2015; 10(11):e0142676. PubMed ID: 26599819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo hepatic steatosis drives atherogenic risk in liver transplantation recipients.
    Idowu MO; Chhatrala R; Siddiqui MB; Driscoll C; Stravitz RT; Sanyal AJ; Bhati C; Sargeant C; Luketic VA; Sterling RK; Contos M; Matherly S; Puri P; Siddiqui MS
    Liver Transpl; 2015 Nov; 21(11):1395-402. PubMed ID: 26228654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
    Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
    J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia.
    Mehta A; Lee TB; Alebna P; Grandhi GR; Dixon DL; Salloum FN; Sanyal AJ; Siddiqui MS
    J Clin Lipidol; 2023; 17(6):828-833. PubMed ID: 37957050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between small dense LDL levels and hepatic fibrosis in patients with nonalcoholic fatty liver disease.
    Young Kim S; Mun S; Yu JH; Jin YJ; Ju Suh Y; Cho SH; Lee JW
    Medicine (Baltimore); 2022 Sep; 101(37):e30527. PubMed ID: 36123875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irisin in patients with nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Anastasilakis AD; Geladari EV; Mantzoros CS
    Metabolism; 2014 Feb; 63(2):207-17. PubMed ID: 24140091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: A focus on atherogenic dyslipidemia.
    Amor AJ; Pinyol M; Solà E; Catalan M; Cofán M; Herreras Z; Amigó N; Gilabert R; Sala-Vila A; Ros E; Ortega E
    J Clin Lipidol; 2017; 11(2):551-561.e7. PubMed ID: 28502513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The inflamed liver and atherosclerosis: a link between histologic severity of nonalcoholic fatty liver disease and increased cardiovascular risk.
    Alkhouri N; Tamimi TA; Yerian L; Lopez R; Zein NN; Feldstein AE
    Dig Dis Sci; 2010 Sep; 55(9):2644-50. PubMed ID: 19960252
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low- and high-density lipoprotein subclasses in subjects with nonalcoholic fatty liver disease.
    Sonmez A; Nikolic D; Dogru T; Ercin CN; Genc H; Cesur M; Tapan S; Karslioğlu Y; Montalto G; Banach M; Toth PP; Bagci S; Rizzo M
    J Clin Lipidol; 2015; 9(4):576-82. PubMed ID: 26228676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of nonalcoholic fatty liver disease with cardiovascular risk factors in obese adolescents: the role of interdisciplinary therapy.
    Sanches PL; de Piano A; Campos RM; Carnier J; de Mello MT; Elias N; Fonseca FA; Masquio DC; da Silva PL; Corgosinho FC; Tock L; Oyama LM; Tufik S; Dâmaso AR
    J Clin Lipidol; 2014; 8(3):265-72. PubMed ID: 24793347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Lipoprotein Particles and Atherosclerotic Events in Nonalcoholic Fatty Liver Disease.
    Patel S; Siddiqui MB; Roman JH; Zhang E; Lee E; Shen S; Faridnia M; Mintini RJ; Boyett S; Idowu MO; Sanyal AJ; Luketic VA; Siddiqui MS
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2202-2204. PubMed ID: 33007508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease.
    Jiang ZG; Tapper EB; Connelly MA; Pimentel CF; Feldbrügge L; Kim M; Krawczyk S; Afdhal N; Robson SC; Herman MA; Otvos JD; Mukamal KJ; Lai M
    Liver Int; 2016 Aug; 36(8):1213-20. PubMed ID: 26815314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between the small dense LDL level and nonalcoholic fatty liver disease: Possibility of a new biomarker.
    Hwang HW; Yu JH; Jin YJ; Suh YJ; Lee JW
    Medicine (Baltimore); 2020 Jul; 99(28):e21162. PubMed ID: 32664153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.
    Cohen DE; Fisher EA
    Semin Liver Dis; 2013 Nov; 33(4):380-8. PubMed ID: 24222095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis.
    DeFilippis AP; Blaha MJ; Martin SS; Reed RM; Jones SR; Nasir K; Blumenthal RS; Budoff MJ
    Atherosclerosis; 2013 Apr; 227(2):429-36. PubMed ID: 23419204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interpreting lipoproteins in nonalcoholic fatty liver disease.
    Nemes K; Åberg F
    Curr Opin Lipidol; 2017 Aug; 28(4):355-360. PubMed ID: 28441156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.